Combinations with BCR-ABL inhibitors against lymphoma cell lines and with ALK inhibitors against NSCLC cell lines were desirable, wherein all the drug–cell line pairs exhibited synergistic effects. This evidence concerns the gene ABL1 and non-small cell lung carcinoma.